Title:
PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG
Document Type and Number:
WIPO Patent Application WO/2022/197100
Kind Code:
A1
Abstract:
The present invention relates to a compound for enhancing anticancer effects of targeted anticancer agents and chemotherapeutic agents currently in use and, more particularly, to an analog compound of the oligopeptide AQTGTGKT and a composition comprising same, wherein the analog compound exhibits an excellent anticancer effect without any side effects. When the compound according to the present invention is mixed with an anticancer agent for combined treatment, as compared with a control group and each of single treatment groups, a significant synergistic effect in inhibitory effects on cancer growth may be provided. Furthermore, since a low-dose anticancer drug can exhibit an excellent combined anticancer effect, side effects including damage to functions and activities that appear in normal tissues, bone marrow dysfunction, gastrointestinal disturbance, alopecia, anticancer drug resistance, and the like, can be minimized. In addition, the oligopeptide has a smaller molecular weight than that of an antibody, and thus an immune reaction of the oligopeptide is of less concern, and the oligopeptide has the advantage of being easy to permeate into tissue, expecting use in combination with an anticancer agent for various types of cancer.
More Like This:
Inventors:
JEON DO YONG (KR)
MOON CHANG HOON (KR)
SHIN HYUN HEE (KR)
LEE HYE RIM (KR)
KIM JEONG MIN (KR)
LEE JEE YOUNG (KR)
MOON CHANG HOON (KR)
SHIN HYUN HEE (KR)
LEE HYE RIM (KR)
KIM JEONG MIN (KR)
LEE JEE YOUNG (KR)
Application Number:
PCT/KR2022/003692
Publication Date:
September 22, 2022
Filing Date:
March 16, 2022
Export Citation:
Assignee:
L BASE CO LTD (KR)
International Classes:
A61K38/08; A61K31/506; A61K45/06; A61P35/00; A61P35/02
Foreign References:
| US20180057532A1 | 2018-03-01 | |||
| JP2020505326A | 2020-02-20 | |||
| KR20210118764A | 2021-10-01 | |||
| KR20210034947A | 2021-03-31 | |||
| KR20220032699A | 2022-03-15 | |||
| KR20140097607A | 2014-08-06 | |||
| US4554101A | 1985-11-19 |
Other References:
MINJEONG YEON, JAEWHAN BYUN, HYUNA KIM, MISUN KIM, HYUN SUK JUNG, DOYONG JEON, YOUNGMI KIM, DOOIL JEOUNG: "CAGE Binds to Beclin1, Regulates Autophagic Flux and CAGE-Derived Peptide Confers Sensitivity to Anti-cancer Drugs in Non-small Cell Lung Cancer Cells", FRONTIERS IN ONCOLOGY, vol. 8, XP055756617, DOI: 10.3389/fonc.2018.00599
YOUNGMI KIM, HYUNA KIM, DEOKBUM PARK, HANSOO LEE, YUN SIL LEE, JONGSEON CHOE, YOUNG MYEONG KIM, DOYONG JEON, DOOIL JEOUNG: "The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1", ONCOTARGET, vol. 8, no. 8, 21 February 2017 (2017-02-21), pages 13632 - 13651, XP055756625, DOI: 10.18632/oncotarget.14621
MERRIFIELD, J., AMER. CHEM. SOC., vol. 85, 1963, pages 2149 - 54
STEWART ET AL.: "Solid Phase Peptide Synthesis", PIERCE CHEM. CO., 1984, pages 111
H. NEURATHR.L.HILL: "The Proteins", 1979, ACADEMIC PRESS
YOUNGMI KIM, HYUNA KIM, DEOKBUM PARK, HANSOO LEE, YUN SIL LEE, JONGSEON CHOE, YOUNG MYEONG KIM, DOYONG JEON, DOOIL JEOUNG: "The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1", ONCOTARGET, vol. 8, no. 8, 21 February 2017 (2017-02-21), pages 13632 - 13651, XP055756625, DOI: 10.18632/oncotarget.14621
MERRIFIELD, J., AMER. CHEM. SOC., vol. 85, 1963, pages 2149 - 54
STEWART ET AL.: "Solid Phase Peptide Synthesis", PIERCE CHEM. CO., 1984, pages 111
H. NEURATHR.L.HILL: "The Proteins", 1979, ACADEMIC PRESS
Attorney, Agent or Firm:
LEE, Myoung-Jin (KR)
Download PDF: